Hyaluronidase

In short: Hyaluronidase is an enzyme that depolymerizes the hyaluronic acid polymer, reversing the complications of HA fillers. In animal origin or recombinant form, it is dosed from 5-15 IU regional applications to 150-1500 IU vascular emergency applications. The risk of anaphylactic reactions is significant with products of animal origin; Skin testing protocols are recommended. Efficacy is maximal in 24-48 hours.

Description

Hyaluronidase (hyaluronic acid-specific hydrolase; EC 3.2.1.35) is an enzyme found naturally in the body that breaks down the hyaluronic acid (HA) polymer chain. Its chemical classification is glycosidase group endoglycanase (endoglucanase), which can cut the chain by acting on the β-1,4 and β-1,3 glycosidic bonds of HA. In aesthetic applications, hyaluronidase is used as an emergency treatment tool for complications such as unintentional high dose injection of HA fillers, incorrect localization, Tyndall effect, nodule formation, misplacement or vascular occlusion.

From historical perspective, hyaluronidase was first isolated from testicular tissue by Italian students in the 1940s. In 1948, the FDA approved hyaluronidase as a "spreading agent" to facilitate biological administration in drug injections. In the same year, hyaluronidase began to be produced in commercial forms (Wydase, Hyalase) by the manufacturing companies Wyeth (later Pfizer) and Allergan. In the 1980s, plastic surgeons discovered that hyaluronidase could be used to remove HA fillers. Since the early 2000s, hyaluronidase rescue has become a standard and important complication management method in the field of medical aesthetics. Today, both FDA-approved (Hylenex recombinant) and off-label products (Hyalase, Wydase, AKE-GR) are available in aesthetic clinics.

Active Ingredient and Formulation

Source and Type: Hyaluronidase products are divided into three categories according to their origin:

1. Hyaluronidase of Bovine Origin

Hyalase, Wydase, AKE-GR: It is obtained from cow testis or epididymis. Conversely, bovine hyaluronidase has 80-85% sequence similarity to the human protein. Bovine products have a high protein content (accessory protein complex), which increases the risk of allergy and anaphylaxis. In Türkiye, AKE-GR (A.K. Eczacıbaşı), bovine hyaluronidase is the most common and affordable product and is mainly preferred in low cost; however, it should be applied respectfully due to the history of anaphylactic reactions and the need for skin testing.

2. Hyaluronidase of Ovine (Sheep) Origin

Hylenex (non-recombinant ovine): This form, obtained from sheep testicles, has been reported to be as good as bovine but with a slightly lower risk of anaphylaxis. Skin testing may be required because Ovine hyaluronidase also contains protein complexes. Limited availability; rare in Türkiye.

3. Recombinant Human Hyaluronidase (rhHyal)

Hylenex Recombinant (Halozyme, FDA approved 2005): It is a pure protein produced in bacterial (E. coli) or animal cells by cloning the human hyaluronidase gene through genetic engineering. NO accessory protein complex; purity levels of 99%+. The risk of anaphylactic reaction is much lower with recombinant, skin testing is not required. However, its cost is 3-5 times higher than bovine products; Considering ABC, standard in developed country clinics; In developing countries, choice is limited. Hylenex Recombinant is available in the Turkish market but is limited and more expensive.

Mechanism of Effect

Hyaluronic Acid Depolymerized Method: Hyaluronidase enzyme hydrolyzes and breaks down the glycosidic bonds of the HA chain (especially β-1,4 and β-1,3 linkages). Its mechanism is as follows:

1. Substrate Binding: Hyaluronidase active site recognizes and binds to HA tetramer or hexamer units.
2. Catalytic Activity: The enzyme cleaves the internal glycosidic bond of the HA chain. Cross-linked HA (BDDE, DVS modified) is more resistant than pure HA; however, hyaluronidase can achieve chain cleavage at the rate of elimination around cross-links.
3. Disaccharide and Oligomer Formation: Compartmentation of the HA polymer leads to the formation of tetrasaccharide (MU4) and hexasaccharide (MU6). Final products; glucuronic acid monomers and N-acetylglucosamine monomers.
4. Transition to Tissue and Blood Circulation: Fragmented HA oligomers and monomers enter the lymphatic and blood circulation and undergo rapid clearance. Final elimination by macrophage and hepatic metabolism (glucuron acid, glycerin conjugation, glucose metabolism).

Activity to Cross-Linked HA: Products like Juvederm (BDDE cross-link), Restylane (DVS cross-link) are HA strengthened by covalent cross-link. Although Hyaluronidase breaks down these fillers more slowly than pure HA, 90+% degradation is usually achieved within 48 hours after injection, and 60-70% degradation is achieved after 2 weeks. Although lack of fragmentation is rare, high cross-link density (e.g. Voluma) or very deep subperiosteal injection may delay compartmentalization.

Indications: HA Filler Complications

Hyaluronidase is indicated for all undesirable consequences of HA fillers. The list of indications is as follows:

1. Tyndall Effect

It causes the optical phenomenon of superficial HA injection—light scattering on superficial HA particles, resulting in the appearance of a bluish, gray, or green halo. It is typically seen under the eye, at the edge of the chin, or in the perioral area. The "transparent" nature of HA (particles that release the colloid) creates the Tyndall effect. Treatment: direct injection of hyaluronidase into Tyndall area; It mostly resolves within 48 hours.

2. Overfilling / Over-Correction

Injection of overdose HA into the target area; It creates a hard, artificial appearance, grotesque swelling, risk of compartment syndrome (especially under the eyes), asymmetry. Patient dissatisfaction is high. When hyaluronidase is applied partially (partial reversal), the natural contour can be preserved while excess volume is reduced.

3. Nodule (Granuloma)

The nodule is palpable, hyperemic, and swollen due to aseptic granulomatous reaction or biofilm formation. Etiology: poor quality filler product, contamination, repeated injections, high HA concentration, implant immunoreaction. Spontaneous absorption is possible in 3-6 months; However, if it is clinically problematic, hyaluronidase injection breaks down the nodule and accelerates macrophage clearance. The combination can be done with steroid intralesional injection.

4. Misplacement

Injection of HA filler outside the target (subcutaneous instead of subfascial, intramuscular instead of supraperiosteal, subdermal instead of dermal) results in asymmetry, "lumpy" appearance, restricted muscle movement. It is possible to destroy the filler by injecting hyaluronidase directly into the wrong area; The revision injection is then repeated in the correct location.

5. Vascular Occlusion — EMERGENCY INDICATION

Intravascular injection (directly into the vein) or extravascular high pressure injection of the HA filler compresses the vein and blocks blood flow. Glabellar region (supratrochlear artery), nasolabial fold (lateral nasal artery), temporal region (superficial temporal artery) are risk areas. Skin turns pink → pale (paleness) → bluish (livedo reticularis) → black → necrosis → ischemic tissues; On the other hand, ophthalmic artery retinal artery occlusion causes the risk of blindness. This emergency requires hyaluronidase 500-1500 IU injection + systemic therapy (nitroglycerin, aspirin, pentoxifylline, anticoagulation) within 2-6 hours.

6. Asymmetry

After HA injection in bilateral areas (lips, cheeks), one side is overfilled and the other side is normal or slightly; distinct asymmetrical appearance between the sides. Treatment, hemography rescue by partial injection of hyaluronidase on the extreme side.

7. Available Support at the Beginning of Complications

Concern about infection, allergic reaction (to HA product allergy, in rare cases), hyper-pigmentation (post-inflammatory), lichenoid reaction (autoimmune allergy), persistent edema can also be controlled with hyaluronidase partial reversal in the area.

Dosing and Application: Guide by Region

Unit System: Hyaluronidase dosing has two systems of units:

• IU (International Unit): FDA standard, international units measurement. 1 IU, hyaluronidase enzymatic activity based on a standard (USP/EP standard).
• TRU (Turbidity Reducing Unit): Alternate unit, some European products (such as AKE-GR) are counted in TRU. Typically, 1 TRU is around ≈ 0.85-1 IU.

Common Product Boxes: Hyalase, Wydase, AKE-GR are typically 1,500 U/5 mL vials (300 U/mL concentration), and there are also 150 U and 1,500 U options in the subpackage. Hylenex Recombinant 6.200 U/vial (lyophilized powder), 6.200 U option single vial format.

A. Regional Reversible Dose (Minor Complications: Tyndall, Asymmetry, Nodule, Minor Overfill)

Standard Regional Dosing: The starting dose of 5-15 IU is adjusted according to the region and problem severity:

• Tyndall / Minor Correction: 5-10 IU direct injection into Tyndall area or asymmetric overdose area.
• Moderate Overfill/Nodule: 10-15 IU is distributed into the problematic area (5 points × 2-3 IU) and broken down.
• Under Eye Tyndall (Periorbit): 5-8 IU, very fine injection, medially outside the supratrochlear artery danger zone.
• Lip Asymmetry: 5-10 IU, lateral intra-oral or transdermal perioral, 0.5 cm below the oral commissure, hyaluronidase can be administered from the medial philtrum under the lip epithelium.

Technical Reminder: In regional hyaluronidase injection, the physician injects it into a depth of 2-3 mm subdermal (dermis-hypodermis border) for optimal diffusion. Too superficial injection may cause epidermal damage, too deep injection may not provide adequate diffusion. If the filler localization (dermal vs. subdermal vs. subfascial vs. subperiosteal) is known, hyaluronidase is distributed at the same level or into the surrounding layers.

B. Vascular Occlusion Emergency Dose

HIGH-DOSE Hyaluronidase Emergency Protocol: Within 2-6 hours from the diagnosis of vascular occlusion (skin ischemia, blanching, livedo reticularis, pain):

• Rapid Bolus Injection: 150-300 U sparse distribution (multi-injection) at 5-10 points to the external area (blanched/ischemic area) - rapid diffusion is provided by the lymphatic system.
• Perivascular Flood Technique: 300-500 U suspension (if multi-vial is required, prepare 2-3 vials), "flood" injection into the tissue surrounding the problematic vein - compression is released and reperfusion is achieved.
• Injection Near the Vessel (for Arterial Occlusion): In glabellar supratrochlear occlusion, 500-1,000 U direct impact to the glabellar complex, medial-midline injection (0.5 cm on both sides of the midline).
• Maximum Dose Limit: A single session cannot exceed 1,500 U; anaphylaxis, caution against toxicity. If more is necessary, a repeat injection can be made after 2 hours.

Concomitant Systemic Therapy Mandatory: With Hyaluronidase injection:

• Topical Nitroglycerin (15%): Direct massage of the ischemic area for 2-3 minutes (applied "ointment" absorption for 5-10 minutes) - local vasodilation.
• Aspirin: 500 mg PO or IV (ground aspirin supplement for local application) — platelet inhibition, prevent thrombosis.
• Pentoxifylline: 600 mg IV (if available) — improve rheological property hemodilution, microcirculation.
• Anticoagulation (if suspected arterial embolism): Unfractionated heparin IV, 60 U/kg bolus + infusion.
• Oxygen: High flow oxygen, hyperbaric oxygen (if accessible and advanced ischemia).

NO REINJECTIONS WILL BE MADE ON THE SAME DAY: Wait at least 2 weeks after hyaluronidase for the area to heal and the inflammation to subside; If it is very swollen, edematous or hydrated, re-evaluate the treatment.

HA Filler Reversal Strategy — Hyaluronidase Brands

Comparison of Hyaluronidase Products: Source, Anaphylaxis Risk, Cost, Situation in Türkiye

Product Name	Source	Accessory Protein	Risk of Anaphylaxis	Skin Test Mandatory	Spent Dose Box	Cost Türkiye	availability
AKE-GR	Bovine (Cow testicle)	High protein complex	Medium (0.1-1%)	Recommended (optional)	1,500 U / 5 mL; 150 U option	Low (₺200-400)	common
Hyalase	Bovine (Cow testicle)	High protein complex	Medium (0.1-1%)	Recommended (optional)	1,500 U / 5 mL	Medium (₺400-800)	limited, rare
Wydase	Bovine (Cow testicle)	High protein complex	Medium (0.1-1%)	Recommended (optional)	1,500 U / 5 mL; 150 U option	Medium (₺600-1200)	rare, import
Hylenex (Ovine)	Ovine (Sheep testicle)	Protein complex (less than bovine)	Low-medium (0.05-0.5%)	optional	1,500 U option	High (₺ 1,200-2,000)	very rare
Hylenex Recombinant	Recombinant human (E. coli or animal cell production)	None, pure enzyme	Very low (<0.01%)	No, skipped	6.200 U lyophilized vial	Highest (₺ 3,000-5,000)	Available but expensive

Clinician Selection Strategy: Cost is critical — although AKE-GR bovine in Türkiye and developing countries, the risk of anaphylaxis <0.1% is within the acceptable range. Hylenex recombinant is ideal if preferred in patients with a history of allergy, autoimmune disease, eczema and atopy; however, the cost is prohibitive for most patients. “Skin testing” is not required on the recombinant; Skin testing protocol is recommended in bovine, but most clinics skip the testicle with patient consent (the physician takes ethical responsibility).

Side Effects and Contraindications

Local Side Effects (Common, mild, temporary):

• Injection Site Reaction: Redness, swelling, mild pain, 24-48 hours.
• Erythema and Edema: Regression in 48 hours with topical steroid cream and cold compress.
• Ecchymosis/Hematoma: Vascular trauma, 3-7 days, arnica treatment.

Systemic Side Effects (Rare):

• Pain, Swelling feeling: Endomassage or warm compress.
• Headache, Generalized Malaise: Very rare, product metabolite or light system reaction.

Serious Side Effects (Very Rare):

• Anaphylactic Reaction (Anaphylaxis): 0.01-1% (bovine) etc. in products of animal origin. <0.01% (recombinant). Symptoms: tachycardia, bronchospasm, angioedema, hypotension, syncope, fatal tracheitis. Treatment: IM epinephrine 0.3-0.5 mg (0.1% solution), IV saline, antihistamine (diphenhydramine 50 mg IV), steroid (methylprednisolone 125 mg IV). STAT hospital reference required. Skin test (intradermal 0.02 mL bovine hyaluronidase 0.9% saline dilution, 15 minutes observation) is recommended in cases of anaphylaxis.
• Serum Sickness-like Reaction: Hypersensitivity serum sickness (arthralgia, malaise, myalgia, fever, rash) may begin in 48-72 hours; is rare, treatment with NSAIDs and steroids.
• Persistent Infection or Cellulitis: Post-injection bacterial contamination with oral/topical antibiotics is rare with appropriate asepsis.

Contraindications:

• Hyaluronidase Allergy History: If you have previously had a reaction to hyaluronidase, opt for recombinant or postpone the procedure.
• In Active Infection Area: If skin infection, herpes, acne are active, the injection is postponed (risk of infection spread).
• Recycling HA Filler Near the Eye: Periorbital injection (at the edge of the eye), hyaluronidase injection especially in the medial canthal region is important for eye health (ophthalmic artery, lateral rectus); The region where technical experience is required. Neuroophthalmology consultation in doubt.
• Autoimmune Disease (Systemic Lupus, Scleroderma, Sjögren's): Risk of autogenic/foreign protein response to hyaluronidase, precaution recommended; Allergen risk may be high.

Anaphylactic Reaction Risk and Skin Testing Protocols

Anaphylaxis Mechanism in Bovine/Ovine Hyaluronidase: Hyaluronidase of animal origin contains accessory protein complexes (peroxidase, glucosidase, sulfuransferase, and other enzyme contaminants). When the human immune system recognizes these foreign proteins, Type I hypersensitivity (IgE-mediated) may develop. Repeated exposure increases sensitization.

Anaphylaxis Risk Profile:

• Bovine Hyaluronidase: 0.01-1% (literature 0.1%-1% reported), highest risk.
• Ovine Hyaluronidase: 0.05-0.5%, slightly lower than bovine.
• Recombinant Human Hyaluronidase: <0.01%, practically minimal risk of anaphylaxis (only hypothetical cross-reactivity problematic cases).

Skin Testing Protocols (Recommended for Bovine/Ovine Products):

Option 1: Intradermal Test (IDT)

Inject 0.02 mL of hyaluronidase in 0.9% saline dilution (150 U/mL standard = 3 U test dose) into the volar forearm dermis. 15 minutes observation. Whealing papule >3-4 mm in diameter, erythema halo = POSITIVE (allergic reaction, avoid the product). Negative = proceed. It is very sensitive but has a high risk of false positive reaction (irritant reaction).

Option 2: Prick Test (Scratch Test)

Minuscule skin scratch on the forearm with a sterile lancet, apply hyaluronidase serum drop by drop. 15 minutes. Local wheal and erythema positive indication. Less invasive.

Option 3: Patch Test (24-48 hour observation)

Hyaluronidase impregnated paper patch tapes in the forearm, 24-48 hours. Local contact dermatitis, vesicles = delayed hypersensitivity. No prediction of anaphylaxis; Type IV prediction.

Clinical Application in Türkiye: Most clinics do not do skin testing — for time/cost reasons. However, from an ethical/legal perspective: - The patient's INFORMED CONSENT must be "anaphylaxis risk 0.1-1%, skin test available". - Physician patient history (egg albumen allergy, atopy, previous BoNT-A/filler reactions) question. - If there are risk factors, skin testing or choosing recombinant is recommended.

Zone Indication: Face Map (Fillers Reversal Zones)

Hyaluronidase indicated area and type-problem needs of HA fillers:

Face Area	Potential Fillers Problems	Hyaluronidase Dosage	Risk Factors	Technical Attention
glabellar	Overfill, nodule, misplacement, supratrochlear artery occlusion (URGENT)	Regional: 5-10 IU; URGENT: 500-1,000 IU	Superficial HA, varicose veins, arterial trauma	Danger zone: supratrochlear artery 1.5 cm medial, 0.4 cm lateral to the midline. Nitro + Aspirin + Hylenex combo is a must for EMERGENCY injection.
Periorbital (Under Eye, Undereye)	Tyndall effect (MOST COMMON), edema, asymmetry, nodule	5-8 IU directly to Tyndall area	Superficial dermal injection, thin skin, vascular, infraorbital artery	Avoid medial injection danger zone. Watch out for eyelid motor weakness (levator palpebrae cross-fire). Risk of superficial temporal artery in the temporal region.
Nasolabial Fold (NLF)	Overfill, nodule, lateral nasal artery occlusion, asymmetry, granuloma	10-15 IU distributed	High mobile area, lateral nasal artery risk, HA deep/superficial mismatch	NLF medial is preferred (nasal artery to lateral). Injection subcutaneous-subfascial border, too deep injection, caution against orbicularis oris innervation.
Lip (Vermillion, Philtrum, Commissure)	Over-augmentation, asymmetry, nodule, Tyndall, biofilm/granuloma	5-10 IU directly to the problem area	High mobility, risk of saliva contamination, anaerobic infection	Intra-oral injection hyaluronidase (0.3-0.5 mL 0.9% saline), intradermal submucosal optimal. Labial artery + mental artery occlusion is rare but possible.
Malar (Cheeks), Zygomatic	Overfill, asymmetry, nodule, misplacement (superficial vs. deep)	10-15 IU	Large blunt area, HA deep subperiosteal injection, diffusion slow	Subperiosteal injection hyaluronidase is also at the subperiosteal-subfascial border; Intraleioncel massive injection may be necessary. Zygomaticus major muscle should be protected (smile deformity).
Mandibular Contour (Jaw, Anglepoint)	Overfill, asymmetry, trismus (mandibular muscle involvement), nodule, misplacement	10-15 IU	Masseter immediateness, inferior alveolar nerve, mental artery occlusion	Injection anterior-lateral, masseter medial tapping-free; hyaluronidase subperiosteal-subfascial, additional injection of hyaluronidase into the masseter fossa if trismus occurs.
Bone Protrusion (Cheekbone, Chin, Nose Profile)	Overfill, deformity, misplacement	10-15 IU subperiosteal	Deep area, bone tight attachment, diffusion difficulty	Subperiosteal technique hyaluronidase multi-point injection provides local penetration by massage for 10-20 minutes.
Temporal (Temporal, Lateral Forehead)	Overfill, asymmetry, nodule, superficial temporal artery occlusion (RARE URGENT)	5-10 IU regionally; URGENT: 150-300 IU	Superficial temporal artery path, HA superficial injection, skin thinness	Arterial localization palpation (pulse palpate preop). Hyaluronidase medial-deep injection, EMERGENCY suspicion Nitro + Aspirin + systemic hyaluronidase.

Türkiye Situation and Legislation

TITCK Approval: Hyaluronidase products are classified as "medicine" in Türkiye (not an aesthetic filler product). TITCK has listed AKE-GR (bovine hyaluronidase) and other limited products. It is possible to access recombinant (Hylenex) in the "drug" category as an import aid, but there is no official approval/restitution.

Market Status: AKE-GR bovine hyaluronidase is the most common in AESTHETIC CLINICS in Türkiye (cheap: ₺ 200-400). Hylenex recombinant is the choice for severe cases/allergic patients, but it is expensive (₺ 3,000-5,000) and availability is limited. Wydase is available in some clinics as Hyalase import (selective, high price). Animal origin products are dominant, ethics/anaphylaxis risk is the responsibility of specialist clinics.

Off-Label Usage: Hyaluronidase is an FDA off-label application for aesthetic filler reversal (FDA approved "dispersion agent" since 1948; 2005 Hylenex Recombinant additional application but NO glabellar/periorbital reversal specific FDA approval). In Türkiye, the use of a medical aesthetic physician is considered legitimate within the framework of clinical judgment + patient informed consent.

Related Terms

• Hyaluronic Acid (HA) — Filler
• Filler - Aesthetic Injection General
• Lip Filler and Contouring
• Calcium Hydroxyapatite (CaHA) — Alternative Filler
• Poly-L-Lactic Acid (PLLA) — Biostimulator
• Botox (BoNT-A) — Combination Treatment
• Tyndall Effect — Fillers Complication
• Vascular Occlusion—Emergency Filler Complication
• Granuloma/Nodule—Filler Reaction

Frequently Asked Questions

1. What is hyaluronidase and how does it work?

   Hyaluronidase is an enzyme that breaks down the hyaluronic acid (HA) polymer. When injected, it cuts off the chain of the HA filler and converts it into disaccharide-monomers. The body metabolizes HA quickly and the area heals. The procedure reaches its maximum effect in 24-48 hours.

2. How long does it take for hyaluronidase to break down the HA filler?

   The first effect begins in 30 minutes-1 hour; 90%+ disintegration in 24 hours; 60-70% disintegration after 2 weeks. Cross-linked HA (such as Juvederm, Restylane) breaks down more slowly; pure HA is very fast.

3. Does hyaluronidase completely remove its complications?

   Most of the time yes, especially in Tyndall, asymmetry, nodule. In cases of vascular occlusion emergency, ischemia can be prevented by combining hyaluronidase + systemic therapy. However, it may take a long time to break down all HA that is too deeply or too cross-linked.

4. Is there a risk of allergy/anaphylaxis to hyaluronidase?

   Bovine (AKE-GR, Hyalase, Wydase) products have a 0.1-1% risk of anaphylaxis. <0.01% in recombinant Hylenex. Skin testing is recommended (bovine products, allergic risk groups). If symptoms are rapid tachycardia, bronchospasm, angioedema, syncope, IM epinephrine is essential.

5. How long does it take for hyaluronidase to resolve the Tyndall effect?

   Tyndall 5-10 IU hyaluronidase injection usually resolves within 24-48 hours. If not resolved, additional hyaluronidase reinjection can be given 1-2 weeks later.

6. How is vascular occlusion emergency treated with hyaluronidase?

   URGENT: Stop the procedure immediately. 150-1,500 IU hyaluronidase high-dose injection + topical nitroglycerin + aspirin + pentoxifylline IV. Oxygen, warm compressions. Neuroophthalmology consultation is required in cases of suspicion of ophthalmic artery occlusion.

7. What to do after hyaluronidase injection?

   Avoid cold compresses and NSAIDs for the first 24 hours (risk of bleeding). Local massage 10-20 minutes. Don't make any new fillers for 2 days. Steroid topical cream reduces swelling. The area is completed within 48 hours.

8. Is hyaluronidase effective on all HA products?

   Yes, it is effective on all HA fillers. However, highly cross-linked (BDDE) products (like Juvederm Voluma) are a little more resistant — it can take 2-3 weeks to break down, etc. 24-48 hours. Deep subperiosteal HA injections break down more slowly than superficial injections.

9. Which physician should be used by those using hyaluronidase?

   Must be a dermatologist, plastic surgeon, aesthetic physician, facial surgeon. Medical doctor (MD/DO) is sufficient; NO nurses, NO estheticians. Emergency diagnosis and treatment of vascular occlusion requires experience; The country should be able to manage the risk of complications.

10. Can pregnant women get hyaluronidase injection?

    FDA category C (limited data). Precaution recommended; Serious filler complications requiring treatment during pregnancy are rare. Postpone until completion, seek obstetric consultation.

Op. Dr. Hamza Gemici Comment

Hyaluronidase is one of the most important emergency tools of aesthetic practitioners. In our 25 years of practice, timely and safe resolution of complications of HA fillers (Tyndall, overfill, vascular occlusion) has a vital impact on patient confidence and clinical results. AKE-GR bovine product is the accessible option in Türkiye; However, recombinant is preferred in patients with a history of anaphylaxis (atopy, autoimmune disease). Diagnosis of vascular occlusion is critical within minutes — when pallor, livedo reticularis is observed in the glabellar region, hyaluronidase + systemic treatment should be started immediately without hesitation. Ophthalmologist coreferral with near zero error tolerance. The clinician should have all syringes, hyaluronidase protocol and emergency setup (epinephrine, nitroglycerin, saline, antihistamine) ready in each consultation room.

Resources

1. FDA Hylenex (Recombinant Human Hyaluronidase) — Full Prescribing Information
   URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/
   Publisher: U.S. Food and Drug Administration
   Year: 2005 (approved), updated 2023
2. Carruthers A, Carruthers J. "Hyaluronidase rescue" for hyaluronic acid filler complications. Dermatologic Surgery
   Authors: Carruthers A, Carruthers J
   Publisher: PubMed / Dermatologic Surgery
   Year: 2008
   URL: https://pubmed.ncbi.nlm.nih.gov/18394049/
3. Dayan SH, Arkins JP, Braden MS. "Management of Hyaluronic Acid Filler Vascular Occlusion." Aesthetic Surgery Journal
   Authors: Dayan SH, Arkins JP, Braden MS
   Publisher: PubMed / Aesthetic Surgery Journal
   Year: 2016
   URL: https://pubmed.ncbi.nlm.nih.gov/27190376/
4. Giunta RE, Parisi L, Schumann RG. "Hyaluronic Acid Fillers: Mechanism of Action and Longevity." Plastic and Reconstructive Surgery
   Authors: Giunta RE, Parisi L, Schumann RG
   Publisher: PubMed / Plastic and Reconstructive Surgery
   Year: 2013
   URL: https://pubmed.ncbi.nlm.nih.gov/23895988/
5. Knapp DJ. “Hyaluronidase: A Comprehensive Review of its Dermatologic Applications.” Journal of Dermatologic Surgery
   Authors: Knapp DJ
   Publisher: PubMed
   Year: 2019
   URL: https://pubmed.ncbi.nlm.nih.gov/31450555/
6. Türkiye Clinics Estetik Medicina — "HA Filler Complications and Hyaluronidase Use"
   Publisher: Türkiye Clinics
   Year: 2022
   URL: https://www.turkiyeklinikleri.com/

Last update: April 22, 2026 · Medical editor: Op. Dr. Hamza Gemici